Christiaan Mulder

Senior Epidemiologist

Christiaan Mulder is a senior epidemiologist with a PhD in Epidemiology and 15 years experience designing and leading epidemiological research (cost-effectiveness, diagnostic accuracy, and intervention studies), and supporting and training health staff in data collection and management and statistical data analysis.

Christiaan has undertaken extensive research on TB diagnostics, contact tracing and TB control and is an expert the implementation of short tuberculosis preventive treatment (TPT) regimens, optimising treatment delivery models, developing evidence-based guidelines, algorithms and monitoring and evaluation systems for capturing key treatment indicators, and health economic modelling.

Within KNCV, Christiaan is the chair of the KNCV Task Force Research and Epidemiology and technical lead on the Unitaid funded IMPAACT4TB project, overseeing the implementation of TPT regimen in Ethiopia, Indonesia, Malawi, and Tanzania. Christiaan supports countries with the implementation of new treatment regimens, developing monitoring and evaluation systems, and conducting qualitative and mixed-methods research, including feasibility and acceptability studies for new TB drugs and regimens, service delivery models, and COVID-19 self-testing. Christiaan also provides technical assistance for the design and implementation of drug resistance surveys, optimal screening and diagnostic algorithms (including Xpert MTB/RIF and CAD4TB) and supports National TB Programs with the development of National Strategic Plans based on the ‘people- centred framework for tuberculosis programme planning and prioritization’

Recent publications

  1. Spruijt I, Erkens C, Greenaway C, Mulder C, Raviglione M, Villa S et al. Reducing the burden of TB among migrants to low TB incidence countries. Int J Tuberc Lung Dis. 2023 Mar 1;27(3):182-188.
  2. Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, Lyakurwa D. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort. Trop Med Int Health. 2023 May;28(5):357-366.
  3. Salazar-Austi N, Mulder C, Hoddinott G, Ryckman T, Hanrahan CF, Velen K, Chimoyi L, Charalambous A, Chihota, VN. Preventive Treatment for Household Contacts of Drug-Susceptible Tuberculosis Patients. Pathogens 2022, 11(11), 1258
  4. Mitiku P, Scholten JN, Getachew M, Mulder C. 3HP nearly doubled the uptake of TB preventive treatment among PLHIV newly initiated on ART in Ethiopia. IJTLD. 2022; Apr 1;26(4):381-382.
  5. Mulder C, Rupert S, Setiawan E, Mambetova E, Edo P, Sugiharto J, et al. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Glob Health. 2022;7(1).


read all the KNCV publications

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.